FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol Treatment

The U.S. FDA has granted approval to Merck's Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor available for adults with high cholesterol, including those with heterozygous familial hypercholesterolemia. This new once-daily pill offers an alternative to existing injectable therapies, demonstrating significant reductions in LDL cholesterol during trials.